{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:49:22Z","timestamp":1788274162736,"version":"build-2803163510"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"abstract":"<jats:p>Advanced malignant melanoma (MM) is treated with immune checkpoint inhibitor (ICI) therapy, which often results in several immune-related adverse events. Fulminant type 1 diabetes mellitus (T1DM) is a rare, rapidly progressive, life-threatening disease. Here, we summarize 8 cases of MM with ICI-induced T1DM and describe one case that developed fulminant T1DM due to nivolumab therapy. We retrospectively reviewed patients treated with ICI from 2014 to 2021 at our hospital. The clinical features and risk factors of ICI-induced T1DM were discussed. ICIs were administered to 426 MM patients at our hospital. Among these, nivolumab was administered in 5 cases, pembrolizumab in 1 case, and the combination of nivolumab and ipilimumab in 2 cases. The frequency of ICI-associated T1DM was 1.88%. The mean glycated hemoglobin level at T1DM onset was 8.0 \u00b1 1.0%. Of the patients, 75% were diagnosed with fulminant T1DM, 62.5% developed diabetic ketoacidosis, and 25% had glutamic acid decarboxylase (GAD) antibodies (an early predictive marker for T1DM). The mean interval between the first ICI administration and T1DM development was 201 \u00b1 187 days. The mean duration of resumption was 13 \u00b1 7 days. We should monitor for T1DM development following treatment with ICIs. ICI can be continued to be used to treat MM if insulin therapy successfully controls T1DM.<\/jats:p>\n          <jats:p>A 67-year-old patient who received adjuvant nivolumab therapy developed fulminant T1DM and thyrotoxicosis 57 days later and tested positive for GAD antibodies. Subsequently, he developed hypophysitis and an isolated adrenocorticotropin deficiency. He continued receiving nivolumab along with self-injected insulin without developing recurrence.<\/jats:p>","DOI":"10.1097\/md.0000000000030398","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T16:01:59Z","timestamp":1662134519000},"page":"e30398","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9134-4794","authenticated-orcid":false,"given":"Akihiro","family":"Ishiguro","sequence":"first","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-7100","authenticated-orcid":false,"given":"Dai","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Hiki","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yamakawa","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Jinnai","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Tsutsui","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Namikawa","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8 + T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s13340-016-0276-9","article-title":"Immune checkpoint therapy and type 1 diabetes","volume":"7","author":"Ikegami","year":"2016","journal-title":"Diabetol Int"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdi.12024","article-title":"Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute\u2010onset Type 1 Diabetes Mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa","year":"2012","journal-title":"J Diabetes Investig"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7861\/clinmed.2020-0054","article-title":"Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?.","volume":"20","author":"Kyriacou","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/jdi.13450","article-title":"Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor-related and conventional","volume":"12","author":"Imagawa","year":"2021","journal-title":"J Diabetes Investig"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/1346-8138.15246","article-title":"Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: a single-center retrospective study in Japan","volume":"47","author":"Otsuka","year":"2020","journal-title":"J Dermatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13340-015-0247-6","article-title":"Risk factors for sudden death and cardiac arrest at the onset of fulminant type 1 diabetes mellitus","volume":"7","author":"Baden","year":"2015","journal-title":"Diabetol Int"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy","volume":"10","author":"Baden","year":"2018","journal-title":"Diabetol Int"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(94)92521-6","article-title":"Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease","volume":"343","author":"Tuomilehto","year":"1994","journal-title":"Lancet"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature","volume":"22","author":"Lo Preiato","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00125-009-1539-9","article-title":"Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset","volume":"52","author":"Kawabata","year":"2009","journal-title":"Diabetologia"},{"key":"R15-20250504","first-page":"212","article-title":"Eine biglandulare Erkrankung (Nebennieren und Schilddr\u00fcse) bei Morbus Adisonii","volume":"21","author":"Schmidt","year":"1926","journal-title":"Verh Dtsch Ges Pathol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMra1713301","article-title":"Autoimmune polyendocrine syndromes","volume":"378","author":"Husebye","year":"2018","journal-title":"N Engl J Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00262-020-02699-1","article-title":"Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review","volume":"70","author":"Zhao","year":"2021","journal-title":"Cancer Immunol Immunother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:35:12Z","timestamp":1746333312000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":17,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030398","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}